222 related articles for article (PubMed ID: 37120689)
21. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms.
Zhang Y; Wu J; Qin T; Xu Z; Qu S; Pan L; Li B; Wang H; Zhang P; Yan X; Gong J; Gao Q; Gale RP; Xiao Z
Leukemia; 2022 Dec; 36(12):2875-2882. PubMed ID: 36224330
[TBL] [Abstract][Full Text] [Related]
23. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
24. The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients.
Wang X; Wang J; Wei S; Zhao J; Xin B; Li G; Zhao J; Wu D; Luo M; Zhao S; Chen Y; Liu H; Zhang H; Wang J; Wang W; Wang H; Xiong H; He P
Front Med (Lausanne); 2023; 10():1165445. PubMed ID: 37435533
[TBL] [Abstract][Full Text] [Related]
25. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.
Tang G; DiNardo C; Zhang L; Ravandi F; Khoury JD; Huh YO; Muzzafar T; Medeiros LJ; Wang SA; Bueso-Ramos CE
Hum Pathol; 2015 Jan; 46(1):65-73. PubMed ID: 25387813
[TBL] [Abstract][Full Text] [Related]
26. Pediatric acute myeloid leukemia as classified using 2008 WHO criteria: a single-center experience.
Davis KL; Marina N; Arber DA; Ma L; Cherry A; Dahl GV; Heerema-McKenney A
Am J Clin Pathol; 2013 Jun; 139(6):818-25. PubMed ID: 23690127
[TBL] [Abstract][Full Text] [Related]
27. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
28.
Ball S; Loghavi S; Zeidan AM
Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
[TBL] [Abstract][Full Text] [Related]
29. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
[TBL] [Abstract][Full Text] [Related]
30. Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification.
Jung J; Cho BS; Kim HJ; Han E; Jang W; Han K; Lee JW; Chung NG; Cho B; Kim M; Kim Y
Ann Lab Med; 2019 May; 39(3):311-316. PubMed ID: 30623623
[TBL] [Abstract][Full Text] [Related]
31. Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
Tawana K; Drazer MW; Churpek JE
Leukemia; 2018 Jul; 32(7):1482-1492. PubMed ID: 29483711
[TBL] [Abstract][Full Text] [Related]
32. [AML in Adults - An Update on Diagnosis, Risk Classification and Therapy].
Spiekermann K; Shen AS
Dtsch Med Wochenschr; 2018 Sep; 143(18):1297-1303. PubMed ID: 30199909
[TBL] [Abstract][Full Text] [Related]
33. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
[TBL] [Abstract][Full Text] [Related]
34. Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours.
Molica M; Perrone S
Expert Rev Hematol; 2022 Nov; 15(11):973-986. PubMed ID: 36271671
[TBL] [Abstract][Full Text] [Related]
35. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
Weinberg OK; Seetharam M; Ren L; Seo K; Ma L; Merker JD; Gotlib J; Zehnder JL; Arber DA
Blood; 2009 Feb; 113(9):1906-8. PubMed ID: 19131546
[TBL] [Abstract][Full Text] [Related]
36. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
37. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
[TBL] [Abstract][Full Text] [Related]
38. Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC.
Huber S; Baer C; Hutter S; Dicker F; Fuhrmann I; Meggendorfer M; Pohlkamp C; Kern W; Haferlach T; Haferlach C; Hoermann G
Leukemia; 2023 Oct; 37(10):2138-2141. PubMed ID: 37573403
[No Abstract] [Full Text] [Related]
39. Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes.
Fang H; He R; Chiu A; Viswanatha DS; Ketterling RP; Patnaik MS; Reichard KK
Am J Clin Pathol; 2020 Apr; 153(5):656-663. PubMed ID: 31977035
[TBL] [Abstract][Full Text] [Related]
40. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
Weinberg OK; Siddon A; Madanat YF; Gagan J; Arber DA; Dal Cin P; Narayanan D; Ouseph MM; Kurzer JH; Hasserjian RP
Blood Adv; 2022 May; 6(9):2847-2853. PubMed ID: 35073573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
